AstraZeneca's (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "hold" rating reissued by stock analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Tuesday,Digital Look reports. They presently have a £110 ($149.72) target price on the biopharmaceutical company's stock. Deutsche Bank Aktiengesellschaft's price target would indicate a potential upside of 8.06% from the company's current price.

Several other analysts have also recently commented on AZN. Berenberg Bank reiterated a "buy" rating and issued a GBX 140 ($1.91) price target on shares of AstraZeneca in a research note on Friday, May 16th. Shore Capital reiterated a "buy" rating on shares of AstraZeneca in a research note on Tuesday, April 29th.

AstraZeneca Trading Down 0.4%

Shares of AZN stock opened at £101.80 ($138.56) on Tuesday. AstraZeneca has a 1 year low of GBX 9,573.51 ($130.30) and a 1 year high of £133.88 ($182.22). The firm has a fifty day moving average price of £104.68 and a 200-day moving average price of £108.76. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The company has a market cap of £195.87 billion, a price-to-earnings ratio of 27.90, a PEG ratio of 0.86 and a beta of 0.17.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.